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Abstract
Background: Sub-Saharan Africa (SSA) alone has nine out of every 10 children living with HIV globally and monitoring
in this setting remains suboptimal, even as these children grow older. With scalability of antiretroviral therapy (ART),
several HIV-infected children are growing towards adolescence (over 2.1 million), with the potentials to reach
adulthood. However, despite an overall reduction in HIV-related mortality, there are increasing deaths among
adolescents living with HIV (ADLHIV), with limited evidence for improved policy-making. Of note, strategies for
adolescent transition from pediatrics to adult-healthcare are critical to ensure successful treatment response and longer
life expectancy. Interestingly, with uptakes in prevention of mother-to-child transmission, challenges in ART programs,
and high viremia among children in SSA, the success rate of paediatric ART might be quickly jeopardised, with possible
HIV-1 drug-resistance (HIVDR) emergence, especially after years of paediatric ART exposure. Therefore, monitoring ART
response in adolescents and evaluating HIVDR patterns might limit disease progression and guide on subsequent ART
options for SSA ADLHIV.
Objectives: Among Cameroonian ADLHIV receiving ART, we shall evaluate the rate of immunovirologic failure,
acquired HIVDR-associated mutations, HIV-1 subtype distribution, genetic variability in circulating (plasma) versus
archived (cellular) viral strains, and HIVDR early warning indicators (EWIs) at different time-points.
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Methods: A prospective and observational study will be conducted among 250 ADLHIV (10–19 years old) receiving
ART in the centre region of Cameroon, and followed-up at 6 and 12months after enrollment. Following consecutive
sampling at enrolment, plasma viral load and CD4/CD8 count will be measured, and genotypic resistance testing (GRT)
will be performed both in plasma and in buffy coat for participants experiencing virological failure (two consecutive
viremia > = 1000 copies/ml). Plasma viral load and CD4/CD8 will be monitored for all participants at 6 and 12months
after enrolment. HIVDR-EWIs will be monitored and survival analysis performed during the 12months follow-up.
Primary outcomes are rates of virological failure, acquired-HIVDR, and mortality.
Discussion: Our findings will provide evidence-based recommendations to ensure successful transition from
paediatrics to adult ART regimens and highlight further needs of active ART combinations, for reduced morbidity and
mortality in populations of ADLHIV within SSA.
Keywords: HIV, Antiretroviral therapy, Adolescents, Cameroon
Background
Sub-Saharan Africa (SSA) alone carries 69.9% of the 36.9
million people infected worldwide and 65.8% of the 1.2
million the global AIDS-related deaths by end 2014, the
majority occurring among adolescents [1]. With the
highest burden of paediatric HIV infections (2.3 million),
about nine out of every 10 children living with HIV
found in the SSA region. With about 86.4% of the 220,
000 newly infected children worldwide by end 2014 [1],
the number of children living with HIV/AIDS will
continuously increase overtime, thereby predicting a
growing rate of adolescents living with HIV (ADLHIV) in
this region. In this line, the burden of HIV/AIDS consti-
tutes a continuous major threat for the future develop-
ment of SSA countries, and therefore remains a leading
poverty-related disease in the entire continent [1–3].
With the advent and scalability of Antiretroviral therapy
(ART), there is a global decrease in AIDS-related deaths.
Of note, 15.8 million people living with HIV were acces-
sing ART as of June 2015, of which 67.7% were from SSA.
Interestingly, about 94% of all children receiving ART are
from SSA, a number expected to reach 1.5 million chil-
dren by 2020 [1, 2]. In this context of continuous new
HIV paediatric infections and increasing coverage in
paediatric ART, the number of children living with HIV
will increase, suggesting a higher likelihood of reaching
adolescent age and even adulthood if treatment regimens
remain fully effective in controlling HIV infection [2–4].
Most importantly, out of about three million children are
living with HIV, an estimated 2.1 million were ADLHIV
(10–19 years of age) in resource-limited settings (RLS) by
end 2012, with a consistent rising of HIV-related deaths in
these ADLHIV even though regressions are seen in other
target populations (younger children, pregnant women,
adults living with HIV/AIDS) [5]. ADLHIV therefore con-
stitutes an HIV population with growing health concerns
and with very limited findings for generalisable best
practices specific to this target population, especially in
SSA whereby, compared to the western world, there is
persistent suboptimal monitoring strategies in routine
practice [6–8].
With the increasing scale-up of ART, as high as 20%
of children might experience virological failure (VF) in
RLS, in the frame of high-levels of viremia generally
observed in children. Moreover, as these children grow
older, there are increasing risks of treatment failure
associated to the development of HIV drug resistance
(HIVDR), particularly with the limited therapeutic op-
tions available for clinical management [7, 8]. Current
paediatric first-line regimens consist of lamivudine, plus
abacavir or zidovudine, plus ritonavir-boosted lopinavir
(LPV/r) or nevirapine (NVP), depending on the mother-
child pair’s history of prevention of mother-to-child
transmission (PMTCT) [6]. of note, LPV/r overcomes
non-nucleoside reverse transcriptase inhibitor (NNRTI)
resistance resulting from PMTCT exposure [2, 3, 9],
while NVP matches with current postnatal prophylaxis
[3, 8, 9]. The success of this lifelong paediatric treatment
will largely depends on the effectiveness of the
combination ART from childhood and monitoring
overtime [8–14]. Current uptakes in PMTCT interven-
tions and universal ART for children suggest that any in-
fected child stands at high risk of transmitted or acquired
HIVDR. Such risks are likely higher in a context whereby:
(1) PMTCT practices have been varying overtime (from
single dose nevirapine, AZT, to options B and B+), (2)
commonly available antiretrovirals are drugs with low
genetic-barrier to resistance, (3) drug stock-outs are
frequently reported and (4) poor adherence remains chal-
lenging. Furthermore, these factors are associated with
clinical challenges of which the high viremia in children
and the limited laboratory monitoring offer room for
delayed detection of treatment failure with accu-
mulation of HIVDR mutations at rates as high as 80%
[8, 10, 11, 15–21]. This situation limits therapeutic
option as children grow older in SSA, thereby appeal-
ing for effective public health strategies for optimal
sequencing of ART regimens, in order to maximise
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long-term treatment success and reduce AIDS-related
morbidity and mortality in these RLS [8]. Most im-
portantly, as older children require transitioning from
pediatrics to adult ART regimens, sustaining long-
term viral suppression prompts the need for reduced
risks for mortality among ADLHIV in SSA [5]. With
scarcity of evidence that reduces disease progression
while preserving next therapeutic options for this
growing population of individuals in SSA, there is
need to implement an assessment that would guide
efficient public health strategies in ART program per-
formance for adolescents [2, 8].
As VF is generally associated with emerging HIVDR,
assessing drug resistance mutations (DRMs), in the
context of a failing regimen, provides clinical benefit and
reduced mortality [9, 10, 22]. An evidence guiding selec-
tion of first- and second-line pediatric ART regimens,
revealed an urgent need for alternative pediatric treat-
ment options in RLS [23]. Furthermore, Kityo et al. in
Uganda revealed high prevalence of pre-treatment
HIVDR and a decreasing burden as children grew older
(10% of all children versus 15.2% of children < 3 years),im-
plying that adolescents might have archived resistant
strains after years of chronic infection [24]. Similar find-
ings from East-Southern Africa reported high-levels of
pediatric HIVDR, ranging from 29 to 77% based on
PMTCT history, and decreasing rates of DRMs with in-
creasing ages, thus confirming the fading-up of resistant
strains over the fitness of wild-type species [11].
As aforementioned, DRMs fade-up as children grow
older, and might remain occult in minority viral
populations or in the cellular reservoirs [25]. For adoles-
cents vertically infected with HIV, the mechanism of oc-
cult HIVDR might be driven by archiving in cellular
reservoirs, due to the long-term chronic infection. Of
note, our studies among children (aged 1–12 years) with
wild type viruses revealed minority DRMs only at early
age (1 year), supporting the fact that ADLHIV stand at
higher chances of harbouring archived DRMs [26]. Of
note, theseoccult resistant variants might remain hidden,
ready to repopulate plasma from tissues/reservoirs under
pharmacological pressure [11]. The potential presence
and the eventual relevance of these minority variants in
paediatric settings can be substantial, and merit
attention in the frame of limited therapeutic regimens.
Demonstrating the clinical implications of such archived
DRMs remains an important unmet medical need [26]. In
this light, assessing such archived DRMs among adoles-
cents might provide complementary information with an
added value for the sequencing of fully active ART combi-
nations, and in turns increase their life expectancy.
When evaluating the efficacy of first- and second-line
pediatric ART regimens in RLS, Boerma et al. reported
the necessity to set-up salvage pediatric therapies that
could be affordable options in RLS [23]. This entails an
eventual need of newer second-line or third-line ART
regimens. In this line, we earlier demonstrated the
absence of major DRMs in the integrase region among
ART-naïve, first- and second-line treated patients
(including adolescents) in Cameroon, thus indicating a
potential efficacy of integrase inhibitors (raltegravir, elvi-
tegravir or dolutegravir) even in heavily treated patients
[27, 28]. Furthermore, we also studied CXCR4 and
CCR5 viral tropism to determine possible use of anti-
CCR5. Our data revealed high rates of X4-tropic viruses
among Cameroonian patients, thereby suggesting poor
outcomes of CCR5 antagonists (i.e. maraviroc) if used
for a public health approach (i.e. without tropism
testing) [27–30]. Most importantly, our data from next
generation sequencing revealed R5-variants prevailing
among children under five years old [26], with increasing
proportions of X4-variants, in accordance with previous
reports [29, 30]. Thus, pending prospective investiga-
tions, a potential salvage ART regimen for adolescents
failing ART might contained fully active reverse tran-
scriptase inhibitors (RTIs) and/or protease inhibitors in
combination with integrase inhibitor (raltegravir), as an
affordable public health approach in RLS [14, 27, 28].
Within the SSA-settings, few studies have addressed
the needs of ADLHIV. In South-Africa, a study compar-
ing treatment outcomes between adolescents versus
young adults at a public sector community-based ART
revealed lower virological suppression rates and higher
rates of VF among adolescents [31], thus underscoring
the necessity for closer monitoring strategies and the
eventual needs of subsequent salvage therapies [23]. In
the Central African Republic, an assessment of virologic
response and DRMs revealed 34% of children in need of
a second-line ART after first-line failure, while 47% of
those under second−/third-line ART were experiencing
VF with at least one major DRM to RTIs, thus calling
for urgent need for improved pediatric ART and monitor-
ing strategies. Among Cameroonian children (aged up to
12 years), we earlier reported high rates (~ 90%) at first-
line failure, after a median-time-on-ART of about two
years only. Second-line guided by sequencing data showed
~ 70% with virological suppression and ~ 90% with
viremia less than 1000 copies/ml. HIV-1 diversity did not
interfere with emerging DRMs and CD4 showed a poor
sensitivity is predicting treatment response [18]. However,
data on medium- to long-term follow-up are completely
missing, and recent findings showed potential implications
of genetic diversity on virological response, especially
among CRF02_AG infected populations [32–35], with
considerable programmatic challenges as in Cameroon
[36, 37]. While attempting to ascertain AIDS events
among adolescents, Sharp et al. reported that, among ver-
tically infected adolescents, the region of HIV-1-Gag
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targeted by CD8+ T cells as well as the magnitude of
CD8+ response may have a clinical importance on moni-
toring disease progression [38]. With limited evidence
in the management of ADLHIV in SSA, it would
therefore be of great asset to thoroughly evaluate the
immunovirologic response in this target population,
in order to identify individual and programmatic fac-
tors to be tackled for improved quality of life and life
expectancy among ADLHIV. Such analysis will help in
tailoring treatment response, resistance profiling and ad-
equacy to subsequent (second- or third-line) ART regi-
mens for ADLHIV in need of newer therapeutic options
in SSA.
The READY-Study (Resistance Evolution among
Adolescents in Yaoundé and its surroundings) aimed at
generating information towards improved recommen-
dations for a successful long-term management of
ADLHIV in SSA, with adequate and affordable transi-
tion policies from paediatric to adult ART regimens
in these RLS. Among Cameroonian adolescents (10–
19 years old) receiving ART, we shall monitor the
therapeutic response to first- and second-line regi-
mens, drug resistance profiling and HIV-1 genetic
variability during one-year follow-up. In this popula-
tion of adolescents receiving ART in Cameroon, we
shall: (1) Evaluate the rate of immunovirologic failure
in the entire population at enrolment, month-6 and
month-12 follow-up points; (2) Evaluate acquired
DRMs and HIV-1 subtype distribution among those
experiencing VF at enrolment, month-6 and month-
12 follow-up points; (3) Evaluate the genetic variabil-
ity in circulating (plasma) versus archived (cellular)
viral strains among those experiencing VF at enrol-
ment, month-6 and month-12 follow-up points; (4)
Evaluate HIVDR early warning indicators (EWIs),
including survival analysis, in the entire study popula-
tion through out the one-year monitoring period.
Methods/design
Study design
A prospective and observational study will be conducted
among ADLHIV receiving ART as per the national ART
programme in Cameroon, with follow-up at 6 and 12
months after enrollment.
ADLHIV on ART will be enrolled from four health fa-
cilities in the centre region of Cameroon, consisting of:
 Two health facilities from the referral treatment
centres (the Mother-Child Centre of the Chantal
BIYA foundation and the National Social Welfare
hospital, both in Yaoundé);
 Two health facilities from the management units
(the Mbalmayo District Hospital in Mbalmayo and
the Mfou District hospital in Mfou).
After enrolment (month-0), follow-up will be done at
mid-point (month-6) and at end-point (month-12),
assessing immunological and virological response,
including HIV-1 genotypic resistance testing (GRT) in
case of confirmed treatment failure.
Description of study setting
In Cameroon, a country with a generalised HIV
epidemiology (4.3% prevalence in the general popula-
tion) and a broadly diverse HIV strains (with the
prevailing CRF02_AG recombinant) [32–36, 39], the
centre region is among sites with high HIV burden
(6.1%), and the locality of Yaoundé and its surround-
ing have a prevalence of 6.3% [40]. HIV prevalence
among vertically infected children is still consistent
(prevalence of 11.5%) in the country [40], and 1.2% of
those aged 15–19 years are infected [39]. Altogether,
these suggest a growing rate of ADLHIV in the coun-
try, with the centre region being among the most
worrying. First-line ART regimens are widely used
(96.3%, consisting of two nucleoside RTIs [NRTIs]
plus one non-NRTI [NNRTI]) and second-line ART
regimens (3.7%, consisting of one protease inhibitor
and two NRTIs) are also available nationwide, with a
total of 122,638 people receiving ART by end 2013
[41]. The most used regimens for adult are zidovu-
dine plus lamivudine plus nevirapine, followed by
tenofovir plus lamivudine plus efavirenz, while for
children zidovudine plus lamivudine plus nevirapine
and zidovudine plus lamivudine plus efavirenz are
predominant [41]. In terms of ART coverage by age
range, 4% of treated patients are aged 0–14 years ver-
sus 91% aged 15 and above (i.e. 5% unknown age),
and adolescents (i.e. aged 10–19 years) are distributed
between these two groups [41]. Importantly, the high-
est coverage of ART is in the centre region (Yaoundé
and its surrounding), followed by the Littoral and the
North-west regions [41]. The national strategic plan
targets 80% ART coverage of children age 0–14 years
by end 2015 [42], thus indicating a growing number
of adolescents on ART.
The choice of the Centre region for the present
study in Cameroon is therefore based on its high
HIV burden, its high coverage of ART, the long-term
experience in ART provision of health facilities [42],
as well as the wide HIV-1 genetic diversity reported
from vertically infected children and adolescents
living in this geographical setting [18].
Sampling method
A consecutive and non-randomised sampling method
will be used for participant enrolment, according to eli-
gibility criteria.
Fokam et al. BMC Pediatrics          (2019) 19:226 Page 4 of 11
Eligibility criteria
Inclusion criteria Will be enrolled in the study
ADLHIV (aged 10–19 years), who are receiving a first- or
second-line ART for ≥6months in one of our study sites,
who provide their written assent, whose legal guardian
accept to provide a written informed consent (in addition
to written assent provided by the adolescent), and
irrespective of PMTCT antiretroviral history (exposed to
PMTCT drugs, not-exposed to PMTCT drugs, or
unknown exposure).
Non-inclusion criteria Will not be considered for en-
rolment ADLHIV not found (i.e. not formally registered)
in the ART monitoring system of a study site, ADLHIV
reported to be ART-naïve, to be on a drug regimen not
included in the national guidelines, or to be on a struc-
tured treatment interruption.
Exclusion criteria Will be considered excluded from
the study any participant who decides deliberately/freely
to withdraw in the course of the study, or transferred
out of a study site before mid- or end-point.
Sample size
Assuming the rate of VF at 40%, a 95% confidence and
80% statistical power, sample size is 174 patients. Adding
10% potential LTFU during the one-year study period
and 20% sequencing failure rate [10, 18], minimal sam-
ple size is 243 ADLHIV, rounded-up to 250 total sample
size, further stratified into 150 ADLHIV in the referral
centres (75 per site) and 100 in the HIV management
units settings (50 per site), as per coverage in ART in
these two geographical locations [41, 42].
Sampling strategy
All ADLHIV meeting study criteria will be invited for a
written assent, as well as their legal guardians for a
written informed consent. Fully consenting participants
will be consecutively enrolled until complete sample size
per site (75 for each of the two HIV referral centres and
50 for each of the two HIV management units). All
participating ADLHIV will be consecutively assigned a
unique ID number per site, and data will be centralised
at the International Reference Centre Chantal Biya
(CIRCB) for research on HIV/AIDS prevention and
management in Yaounde, Cameroon. Physical and
telephone contact details of participants will also be reg-
istered in the database for active follow-up, whenever
necessary, by the study community-relay agents.
Study procedures and variables
Procedures and timeline
Entire schedule requires 30-months overall: 6-months
(month1–6) for administration/ethics/field preparedness,
6-months (Month 7–12) for enrolment of participants
until complete sampling, 12-months monitoring (Month
7–24) for complete follow-up of one-year, and 6-months
(Month 25–30) for closing study sites, data processing,
and reporting. During enrolment (M0) at the clinic,
study clinicians will obtain informed consent and partici-
pant assent from legal guardian and the ADLHIV, re-
spectively, followed by collection of socio-demographic,
clinical and economic data, HIV history (including date
of HIV diagnosis and WHO-clinical staging), complete
history of ARV (ART and/or PMTCT, previous viral load
and CD4/CD8 whenever available), as well as adherence
levels. Intravenous blood (6 ml) will be collected from
each ADLHIV for laboratory analyses at the CIRCB.
Practically, CD4/CD8 (cells/mm [3] and percentage) and
plasma viral load (PVL) will be performed for all
ADLHIV using flow cytometry and real-time polymerase
chain reaction (PCR) respectively. Among those experi-
encing VF, RNA (from plasma) and DNA (from buffy
coat) extracts, isolated using the QIAamp commercially
available Viral RNA and DNA Mini Kit (QIAGEN), be
will be used for PCR-amplification of the protease-
reverse transcriptase (PR-RT) region of HIV-1. GRT will
be performed on PR-RT amplicons using Sanger-
sequencing, as previously described [43]. HIVDR-
associated mutations will be interpreted using Stanford
HIVdb algorithm [18, 35, 36, 43]. GRT results will then
guide the selection of effective ARVs available in the na-
tional ART programme (first-, second-, and third-line
regimens) and outcomes (WHO-clinical staging, viral
and CD4/CD8 measurements) will be measured at 6 and
12month-visits.
Follow-up visits will be at mid-point (monthsMonth 6
[±1]) and at endpoint (Month 12 [±2]) after enrolment
into the study. At each time-point (baseline, mid-point
and end-point), epidemiological and clinical data will be
collected using the same procedure described above dur-
ing enrolment (i.e. baseline), including ART-adherence
assessment. 6 ml of intravenous blood will be collected
per visit (for CD4/CD8 and PVL). Among those experi-
encing VF at these visits, GRT will be performed as
described above [18, 35, 36, 43], and the results will then
guide the selection of effective ARVs available in the
national ART programme for first-, second-, and third-
line regimens.
At each study phase (enrolment, midpoint, endpoint),
residual samples will be stored at − 80° available in the
blood bank of the CIRCB. The entire work plan requires
30-months: 6-months (month1–6) for administration/
ethics/field preparedness, 6-months (Month 7–12) for
enrolment of participants until complete sampling, 12-
months monitoring (Month 7–24) for complete follow-
up of one-year, and 6-months (Month 25–30) for closing
study sites, data processing, and reporting.
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Detailed procedures
At month-0, enrolment will be done at study clinic
for all adolescents meeting study eligibility criteria.
Participants will then be followed up during 12
months after enrolment, with scheduled visits at the
clinic at months 6 (±1 month) and 12 (±2 month), for
a total of 3 scheduled visits. Patients with virological
failure (viral load > 1000 copies/ml) at any timepoint
will undergo an extra visit in the next 1 month with
adherence support and to confirm the virological
failure (VF) as aforedescribed. Participants’ clinical
management not considered in the study protocol will
follow local recommendations for clinical practice at
the discretion of the responsible physician.Procedures
at Baseline visit (month 0). Mothers will be required
to provide data contained in the Baseline Case Report
Form (see clinical data definition below). Briefly, this
will cover detailed epidemiological and clinical infor-
mation, including socio-demographic and economic
data, HIV history, history of antiretroviral usage by
the adolescent, including drugs taken as part of
PMTCT (if applicable), adherence to ART, and results
from any laboratory test that were performed before
study enrolment and available in the patient medical
record file. Blood will be collected from each partici-
pating adolsecent, for a total of volumen 6 ml per
timepoint for the following: determination of: viral
load (600 μl plasma); CD4/CD8 levels (100 μl whole
blood); HIV-1 Sanger sequencing for protease-reverse
transcriptase (1000 μl plasma for RNA extraction and
200 μl buffy coat for DNA extraction); residual plasma
samples will be stored at the biobank.
Laboratory procedures on sample management
plans are provided below. Procedures at follow-up
visits at months 6 and 12. Participants attending
follow-up and their legal gauardians will be required
to provide data contained in the follow-up Case
Report Form, for updated information on epidemio-
logical and clinical situation, with special emphasis on
antiretroviral treatment information and HIV-related
clinical events. Blood samples will be collected as de-
scribed above. Similarly, for plasma viral load > 1000
copies/ml, adherence support will be provide then
GRT performed if and only if virological failure is
confirmed one-month later.All laboratory analysis will
all be performed at the International Reference
Centre Chantal Biya (CIRCB) in Yaounde, Cameroon,
among which: Viral load measurementsWill be per-
formed using Abbott m2000rt, as per the manufac-
turer’s instructions. Briefly, 600 μl of plasma collected
from EDTA tube is used for viral RNA extraction. Based
on the principle of reverse transcription polymerization
(RT-PCR), amplicons are generated from the RNA gen-
ome of HIV-1 in clinical specimens. An RNA sequence
that is unrelated to the HIV-1 target sequence is intro-
duced into each sample at the beginning of sample PCR
mix preparation. This unrelated RNA sequence is simul-
taneously amplified by RT-PCR, and serves as an internal
control (IC) to demonstrate that the process has pro-
ceeded correctly for each sample. The amount of HIV-1
target sequence that is present at each amplification cycle
is measured using fluorescent-labeled oligonucleotide
probes on the Abbott m2000rt instrument. The amplifica-
tion cycle at which an increase in fluorescent signal is de-
tected by the Abbott m2000rt is proportional to the log of
the HIV-1 RNA concentration present in the original pa-
tient sample.CD4/CD8 will be performed using FACSCali-
bur, as per the manufacturer’s instructions. Briefly,
determination of lymphocyte subsets (CD3, CD4, CD8)
will be performed on the flow cytometer (BD Biosciences,
San Jose, CA) using a single-platform technology. A vol-
ume of 50 μl whole blood will be stained with 10 μl of
Multitest reagent in Trucount tubes for 15min (all from
BD Biosciences), and red blood cells will be lysed by using
fluorescence-activated cell sorting lysing solution (BD Bio-
sciences). Data acquisition will be performed using
CellQuest-Pro software (BD Biosciences) creating up to
nine multicolor acquisition dot plots that use eight multi-
color gates. Data will be then analyzed with FlowJo soft-
ware version 7.5.5 for Microsoft (TreeStar, San Carlos,
CA). Using Multitest reagents with Trucount tubes in the
laboratory procedure, absolute subset count will be calcu-
lated with the following formula: (number of events in the
region containing the cell population/number of events in
the absolute count bead region) × (the number of beads
per tube/test volume). If ncessary, a FACSCanto II (alter-
native platform to FACSCalibur) could be used for the
same CD4/CD8 measurement purposes. Briefly, these
analyses will be performed using the FACS Diva software
(BD Biosciences, San Jose, CA), by reading information
from the BD FACSTM 7-color setup beads label into BD
FACSCanto clinical software (2D barcode symbology),
and also by reading coded patient information into a
worklist. Sanger Sequencing for HIV-1 drug resistance
testing will be performed for adolescent experiencing viro-
logical faiure, using ABI 3130xl (Genetic Anlyser with 16
capillaries), HIV genotyping will be performed using
plasma samples and an in-house reverse transcriptase
polymerase chain reaction (PCR) protocol, as previously
described (Fokam et al., 2011). Briefly, RNA will be ex-
tracted from 140 μl of concentrated plasma using the
QIAamp Viral RNA minikit (Qiagen, Milan, Italy), accord-
ing to the manufacturer’s protocol. RNA extracts will then
be retrotranscribed and amplified using the kit One-Step
Invitrogen (Foster City, CA) (SuperScript One-Step for
long templates RT-PCR) and 2 different sequence-specific
primers for 40 cycles. For insufficiently amplified samples
after the first round PCR, a second round PCR (semi-
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nested PCR) will be performed. A direct sequencing reac-
tion will be done using 7–8 overlapping primers. For a full
plate run, the sequencer of 16 capillaries will analyse 2 dif-
ferent patient samples simultaneously for ~ 2.5 h per run,
and assembly program (Seqscape v2.7) will be used for se-
quence analysis, and mutations will be interpreted follow-
ing the Stanford HIVdb algorithm. Therefore, 12 samples
will run for 15 h in total. Study timeline is provided as
Additional file 1: (SDC) 1.
Abstraction of HIVDR EWIs
Data on HIVDR EWIs will also be collected at each
study phase, consisting of five variables among which
EWI1 (on-time pill pick-up), EWI2 (retention in care),
EWI3 (pharmacy stock-outs), EWI4 (dispensing practices),
EWI5 (virological suppression). Among patients not
retained in care during the 12-month follow-up period,
we shall investigate to the underpinning reason that
might be deliberate ART interruption, transfer out or
mortality. Cases of mortality will then serve to deter-
mine the survival rate among the study participants.
Definition of study variables
– VF will be defined as two consecutive PVL ≥ 1000
copies/ml within 1 month under intensive adherence
counselling and support [10]. Participants with
PVL ≥ 1000 copies/ml at
any visit will therefore undergo adherence
counselling and extra-visit after 1 month to confirm
or infirm VF.
– Immunological failure will be defined as persistent
CD4 < 100 cells/mm [3] during follow-up.
– Clinical failure will be defined as WHO clinical stage
3 or 4 events or death. Clinical management outside
the study protocol
will be done according to local national guidelines.
– HIVDR will be defined as the presence of any
mutation, in the PR-RT regions of HIV-1, known
to reduce the efficacy of NRTI, NNRTI or
protease inhibitor, as per the Stanford HIVdb
algorithm [18, 35, 36, 43].
– Good adherence will be defined as ≥95% compliance
to ART (i.e. only one missing dose), measured by pill
count and by self-reported, during the past 30 days.
– EWIs will be defined and their respective
performance targets are provided below: [10, 3, 8]
Quality assurance
For each of the 3 study phases (enrolment, midpoint,
endpoint), quality assurance will be performed by
proficiency testing for PVL, CD4/CD8 (cell/mm [3] and
percentage) and Sanger-based GRT.
Management of potential study risks
Lost to follow-up (LTFU) is a potential risk in reducing the
power of this study for evidence-based recommendations.
EWI and
title
Definition Numerator Denominator Target
EWI1
On-time
pill pick-up
Proportion
of
adolescents
that pick-up
ART no
more than
two days
late at the
first pick-up
after the
baseline
pick-up.
Number of
adolescents
picking-up
their ART
“on time”
at the first
drug pick-up
after baseline
pick-up date
Number of
adolescents
who
picked-up
ARV drugs
on or
after the
designated
EWI
sample
start date
Desirable
performance
(green): >
90%Fair
performance
(amber):
80–90%Poor
performance
(red): < 80%
EWI2
Retention
in care
Percentage
of
adolescents
known to
be alive and
on ART 12
months
after
enrolment
Number of
adolescents
who are still
alive and
on ART
12months
after
enrolment
Total number
of adolescents
(excluding
transfers out)
who were
expected to
achieve
12-month
outcomes
Desirable
performance
(green):
> 85%Fair
performance
(amber):
75–85%Poor
performance
(red): < 75%
EWI3
Pharmacy
stock-outs
Percentage
of months
in the study
period in
which there
were no
ARV drug
stock-outs
Number of
months in
the designated
year in which
there were
no stock-out,
days of any
ARV drug
routinely
used at
the site
12months
of the
reporting
period
Desirable
performance
(green):
100%Poor
performance
(red): < 100%;
EWI4
Pharmacy
dispensing
practice
Percentage
of
adolescents
being
dispensed a
mono- or
dual-ART
Number of
adolescents
who pick up
from the
pharmacy,
a regimen
consisting
of one or
two ARVs;
Number of
adolescents
picking up
ART on or
after the
designated
EWI sample
start date
Desirable
performance
(green) defined
as 0%
adolescents
picking-up a
mono- or dual-
ARTPoor
performance
(red) defined
as > 0%
adolescents
picking-up a
mono- or
dual-ART, and
EWI5
Virological
suppression
Percentage
of
adolescents
receiving
ART of ART
whose viral
load is
< 1000
copies/ml
12months
after
enrolment
Number of
adolescents
receiving
ART 12
months
after study
enrolment
and whose
viral load is
< 1000
copies/ml
Number of
adolescents
who have a
viral load
performed at
12months
after
enrolment
Desirable
performance
(green):
> 85% Fair
performance
(amber):
70–85%Poor
performance
(red): < 70%
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To limit LTFU, adherence support will be intensified and
the site community relay agents will undertake active
search of defaulters.
Investigators’ compliance may be concerning at certain
points of the study (i.e. if a collaborator moves for several
reasons). To handle this potential challenge, site visit will
be conducted weekly and site compliance to study regula-
tions will be assessed by monthly supervision. The lead
applicant will regularly coordinate activities with study-
site clinicians and with guidance from mentor.
Data protection and safety might be concerning. This
will be handle by procurement of a new computer device
and a specific database dedicated exclusively for the pro-
ject, with encrypted password and a protected working
station. Potential bias in laboratory data will be handled
with quality assurance. To ensure functionality of equip-
ment, routine preventive maintenance will be ensured. If
for any unforeseen reason an equipment breakdown, the
backup laboratory (Centre Pasteur du Cameroun) will
covered the required period, under current agreement.
For staff protection, biosafety will be ensured by use of
personal protective equipment as per international
standards, including use of for a biosafety level II cabinet
for project related-laboratory activities.
Data collection and analysis
Data will be collected per site and stored in a password-
protected database at the CIRCB, Yaoundé-Cameroon,
whereby the project statistician will coordinate data
management and analyses using SPSS software. Study
data will consist of sociodemographic, clinical and
laboratory information. Data Management will be under
the responsibility of the project Biostatistician of the
CIRCB in Younde-Cameroon, in coordination with the
principal investigator. Data management will therefore
entail procedures for sociodemographic, clinical and
laboratory data collection, data protection, data quality
assurance and data analysis. This procedure will be
similar at enrolment (M0), midpoint (M6) and endpoint
(M12). Standardized Case Report Forms (CRFs) will be
generated and provided to the four study sites for on-
site collection of data. In addition to basic demographic
information, CRFs will include all clinical information,
as well as information on type of sample collected,
including date, number of aliquots, volume of aliquots
and sample identification numbers to reassure further
tracing of laboratory results. CRFs will be translated and
provided in French and in English as per national
regulations in Cameroon. However, mainly the French
version will be used as the study sites are all within the
French-speaking sector of the country. CRFs will be
completed by the project site collaborator, and double-
checked by a research fellow for consistency, if neces-
sary, the CRF will be correctly completed and signed by
the site principal investigator or other authorised person.
At the end of each study visit, double-checked and
signed CRFs will be sent to data entry. Laboratory CRFs
will be also generated and provided in paper to the cor-
responding local laboratories to introduce laboratory re-
sults, together with identification number of samples. At
the completion of laboratory procedures, laboratory
project staff will be responsible for completion of labora-
tory CRFs, which will be double-checked by the co-
investigator for laboratory analyses and, if necessary, the
CRF will be correctly completed and signed by the site
principal investigator or other authorised person. At the
end of this process, double-checked and signed labora-
tory CRFs will be sent to data entry.Data collected
through clinical and laboratory CRFs will be entered on
site through double entry, by designated data entry
personnel. A specific database will be created for the
protected entry of clinical data and laboratory results.
Data storage will be done in numerical codes generated
consecutively per site. Samples for plasma viral load,
CD4/CD8, and eventually for genotypic resistance test-
ing (in case of treatment failure) to be daily centralised
for analysis at the CIRCB laboratory, using participant
anonymous ID code for their respective sample, along-
side the corresponding sample transportation form. The
laboratory co-investigator at CIRCB or other authorized
person will have full responsibility for the completion of
any procedures.
At enrolment, midpoint and endpoint, prevalence of
VF and HIVDR (with 95% Confidence Intervals) will be
described globally, by geographical settings and by site.
Associated factors will be evaluated using multivariate
logistic regression, with an estimative approach for the
unbiased effect of ART regimens (first versus second-
line) and HIV-1 diversity (CRF02_AG versus non-
CRF02-AG) [18]. In order to provide the highest level of
evidence amongst ADLHIV experiencing VF versus
those on virological success, ART response will be
described through time to event data analysis and mixed
models for the trajectory of CD4 count and viral load,
based on adjustments of baseline confounders (duration
of treatment, age, gender, orphan hood, site). The effect
of DRMs (from plasma versus buffy coat) on ART
response will be evaluated using multivariate survival
models, either Cox or Fine&Gray in the presence of
death as competing event. Characteristics of patients
LTFU will be described and, if necessary, inverse prob-
ability weights will be used. Primary outcome is the pro-
portion of VF; secondary outcome is the proportion of
acquired-HIVDR, or deaths, evaluated according to
study site (referral centres versus management units),
HIV-1 subtype distribution (CRF02_AG versus non-
CRF02-AG) [18], adherence levels (< 95% vs. ≥95%) [44],
and ART regimens (first versus second-line) [35].
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Proportion of adolescents with low-level viremia
(≥400 or ≥ 50copies/ml) who finally end in VF will be
described, along with HIVDR profile at endpoint [45].
We will build a multivariate logistic model with
predictive approach to evaluate the association of
socioeconomic conditions with adherence levels and
HIVDR emergence [44, 46].
Discussion
Our research objectives will help in generating evidence
for optimal monitoring and management of adolescents
treated with antiretroviral therapy (ART) in a sub-
Saharan African (SSA) context. Specifically, study object-
ive 1 will help in understanding the significance of treat-
ment failure among adolescents living with HIV
(ADLHIV) in a resource-limited setting (RLS), will pro-
vide relative time-estimates for treatment failure, and
propose locally affordable measures to limit ART failure
in ADLHIV; study objective 2 will provide the burden of
drug resistance according to the national treatment
guidelines, and would inform on the adequacy between
detected mutations and the most potentially active sec-
ond- or third-line drugs for ADLHIV in such RLS. This
study objective is inform if the development of HIVDR
are specific to the different local HIV-1 clades, for pos-
sible clinical considerations for a specific management
of adolescents in the country; study objective 3 will in-
form on the potential compartmentalisation of HIVDR
among adolescents, in order to design drug combina-
tions that provide maximal efficacy in a long run; study
objective 4 will identify both programmatic factors
favouring HIVDR emergence among ADLHIV, among
which events of ARV stock outs and the quality of dis-
pensing practices. This same objective will also identify
the level of adherence of ADLHIV to ART, among which
non-observance, delay drug pick-up and lost to follow-
up. Importantly, with the exception of settings where
HIV-1 subtype C prevails (found mainly in Southern
Africa), our study impacts could be generalizable to the
population of ADLHIV in several RLS, giving potential
endorsements by national and international health regu-
latory bodies such the World Health Organisation
(WHO) and UNAIDS.
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